대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Potential of Oral Roxadustat as a Novel Treatment of Anemia in Chronic Kidney Disease (CKD): An Update Meta Analysis
저자	Nurul Fajri Widyasari, Rizki Febriawan
출판정보	2020; 2020(1):
키워드	Roxadustat \| Anemia \| CKD
초록	Anemia is complication of Chronic Kidney Disease (CKD) and is associated with significant morbidity and mortality. Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. Literature search was conducted using google scholar, PubMed and scopus until February 2020 to find randomized control trial (RCTs), which assessed Roxadustat on anemia in CKD patients with/without dialysis. Treatment effect were considered as Mean difference and standard deviation (SD) change from the baseline. We performed data analysis using RevMan 5.3. A total of 6 RCTs involving 628 intervention adn 275 control participants were included in the meta analysis. Treatment with Roxadustat significantly raise Hb (0.86, 95% CI, 0,73-0,98; P<0,00001, I= 88%) , TIBC (32.53, 95%CI, 23.56–41.51; P<0.00001, I=96%) and decrease hepcidin level (-31.92, 95% CI, 35.02–28.82; P<0.00001, I=39%) both in dialisis and non dialisis CKD patients compared with control. However, decrease in ferritin level only significant in non-dialisis subgroup (-51.10, 95% CI, 60.82–41.39; P<0.00001, I=55%) and there is no significant change of transferrin saturation in both subgroup. Oral Roxadustat showed efficacy on improving Hb and Iron metabolism in CKD patients both with or without dialysis.
원문(PDF)	PDF 원문보기

목록

위로가기